Advertisement

Organisation › Details
InflaRx N.V., Munich
InflaRx (Nasdaq: IFRX) is a clinical-stage biopharmaceutical company focused on applying its proprietary anti-C5a and C5aR technologies to discover and develop first-in-class or best-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. Complement C5a and its receptor C5aR are powerful inflammatory mediators involved in the progression of a wide variety of autoimmune and other inflammatory diseases. InflaRx was founded in 2007, and the group has offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI, USA. For further information, please visit www.inflarx.de. The COVID-19 related work for vilobelimab was partly funded by the German federal government through grant number 16LW0113 (VILO-COVID). All responsibility for the content of this work lies with InflaRx. *
![]() |
Start | 2022-12-22 existent |
Group | InflaRx (Group) | |
![]() |
Industry | anti-infective drug |
![]() |
Region | Martinsried |
Country | Germany | |
Street | 22 Fraunhoferstr. | |
City | 82152 Martinsried | |
Tel | +49 -89-414-189-7800 | |
Address record changed: 2024-02-23 | ||
Basic data | Employees | n. a. |
* Document for »About Section«: InflaRx N.V.. (12/21/22). "Press Release: InflaRx Announces Amendment of Co-Development Agreement and Additional Equity Investment by Staidson in Connection with Regulatory Filing in China for Anti-C5a-Antibody for Treatment of COVID-19". Jena. | ||
Record changed: 2024-12-29 |
Advertisement

More documents for InflaRx (Group)
- [1] InflaRx N.V.. (8/27/24). "Press Release: InflaRx Announces Participation in September Investor Events". Jena....
- [2] InflaRx N.V.. (6/24/24). "Press Release: InflaRx’s Gohibic (vilobelimab) Selected for First BARDA-sponsored Clinical Trial to Evaluate Novel Host-directed Therapeutics for Acute Respiratory Distress Syndrome (ARDS)". Jena....
- [3] InflaRx N.V.. (2/22/24). "Press Release: InflaRx Appoints Jan Medina as Head of Investor Relations". Jena....
- [4] InflaRx N.V.. (1/25/24). "Press Release: InflaRx Announces Initiation of Its Commitment Program for GOHIBIC (vilobelimab) to Help Broaden Access for Eligible Patients". Ann Arbor, MI....
- [5] InflaRx N.V.. (4/18/23). "Press Release: InflaRx Announces Closing of the Full Exercise of Greenshoe Option Increasing the Proceeds of the Recently Announced Public Offering of Ordinary Shares to US$46 million". Jena....
- [6] InflaRx N.V.. (4/14/23). "Press Release: InflaRx Announces Closing of $40 Million Public Offering of Ordinary Shares". Jena....
- [7] InflaRx N.V.. (4/11/23). "Press Release: InflaRx Announces Public Offering of Ordinary Shares". Jena....
- [8] InflaRx N.V.. (4/11/23). "Press Release: InflaRx Announces Pricing of $40 Million Public Offering of Ordinary Shares". Jena....
- [9] InflaRx N.V.. (4/4/23). "Press Release: InflaRx Receives FDA Emergency Use Authorization for Gohibic (vilobelimab) for Treatment of Critically Ill COVID-19 Patients". Jena....
- [10] InflaRx N.V.. (12/21/22). "Press Release: InflaRx Announces Amendment of Co-Development Agreement and Additional Equity Investment by Staidson in Connection with Regulatory Filing in China for Anti-C5a-Antibody for Treatment of COVID-19". Jena....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement

» top